Lymphocytes in the treatment with interferon beta-1 b

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10368291" target="_blank" >RIV/00216208:11150/17:10368291 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/17:10368291

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.msard.2017.08.020" target="_blank" >http://dx.doi.org/10.1016/j.msard.2017.08.020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2017.08.020" target="_blank" >10.1016/j.msard.2017.08.020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lymphocytes in the treatment with interferon beta-1 b

Popis výsledku v původním jazyce

Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. One of the basic medications for the treatment of a clinically isolated syndrome (CIS) or relapsing-remitting MS is interferon beta (INF beta). Although the exact mechanism of its effects is unknown, the medication has an anti-inflammatory and immunomodulatory effect. The goal of this study was to determine the characters which are affected in patients treated with INF beta. Methods: A total of 97 patients (25 males and 72 females) were included into the study. Patients were treated by INF beta 1-b (subcutaneous injection, 250 mu g, each other day). Clinical evaluations were performed by an attending neurologist. Peripheral blood samples were obtained just prior to treatment and 5 years after INF beta 1-b. Statistical analysis and processing of the obtained data were performed by using a comprehensive statistical software package MATLAB (R). Results: A significant decrease of the observed parameters after 5 years&apos; of treatment (significant at the 1% significance level) was found in the absolute and relative CD69 count, absolute cytotoxic/suppressor T lymphocyte count, absolute total leukocyte count, absolute natural killer cells count. A significant decrease of the observed parameters after 5 years&apos; of treatment (significant at the 5% significance level) was found in the absolute lymphocyte count, relative cytotoxic/suppressor T lymphocyte count, relative CD3+CD69+ count and absolute CD8+CD38+ count. Conclusion: The treatment with interferon beta reduces clinical exacerbations in multiple sclerosis (MS) through several known immunomodulatory mechanisms. However, the exact mechanism of effect of this medication is not known. This study presents some parameters that were affected by the long-term INF beta treatment.

Název v anglickém jazyce

Lymphocytes in the treatment with interferon beta-1 b

Popis výsledku anglicky

Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. One of the basic medications for the treatment of a clinically isolated syndrome (CIS) or relapsing-remitting MS is interferon beta (INF beta). Although the exact mechanism of its effects is unknown, the medication has an anti-inflammatory and immunomodulatory effect. The goal of this study was to determine the characters which are affected in patients treated with INF beta. Methods: A total of 97 patients (25 males and 72 females) were included into the study. Patients were treated by INF beta 1-b (subcutaneous injection, 250 mu g, each other day). Clinical evaluations were performed by an attending neurologist. Peripheral blood samples were obtained just prior to treatment and 5 years after INF beta 1-b. Statistical analysis and processing of the obtained data were performed by using a comprehensive statistical software package MATLAB (R). Results: A significant decrease of the observed parameters after 5 years&apos; of treatment (significant at the 1% significance level) was found in the absolute and relative CD69 count, absolute cytotoxic/suppressor T lymphocyte count, absolute total leukocyte count, absolute natural killer cells count. A significant decrease of the observed parameters after 5 years&apos; of treatment (significant at the 5% significance level) was found in the absolute lymphocyte count, relative cytotoxic/suppressor T lymphocyte count, relative CD3+CD69+ count and absolute CD8+CD38+ count. Conclusion: The treatment with interferon beta reduces clinical exacerbations in multiple sclerosis (MS) through several known immunomodulatory mechanisms. However, the exact mechanism of effect of this medication is not known. This study presents some parameters that were affected by the long-term INF beta treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

neuvedeno

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

29-32

Kód UT WoS článku

000415341300007

EID výsledku v databázi Scopus

2-s2.0-85029529107